Dd. Callas et al., IN-VITRO EFFECTS OF A NOVEL HEMOGLOBIN-BASED OXYGEN CARRIER ON ROUTINE CHEMISTRY, THERAPEUTIC DRUG, COAGULATION, HEMATOLOGY, AND BLOOD-BANKASSAYS, Clinical chemistry, 43(9), 1997, pp. 1744-1748
Red blood cell (RBC) replacement solutions are being developed as alte
rnatives to allogeneic REC use in blood transfusions in the treatment
of massive trauma, to achieve hemodynamic stability during elective su
rgery, and to increase oxygen-carrying capacity in anemia. Hemoglobin-
based oxygen carrier (HBOC)-201 (Biopure Corp.) is a purified, sterile
, isosmotic glutaraldehyde-polymerized bovine hemoglobin. Because this
product is acellular, blood components containing this substance appe
ar hemolyzed. This study reports on the interferences produced by the
presence of HBOC-201 in a variety of clinical assays, This product was
added in vitro at concentrations up to 60 g/L (6.0 g/dL) to normal hu
man serum, plasma, or whole blood before testing for serum chemistries
, coagulation profiles, and hematology and blood bank assays. In addit
ion, a set of normal human sera containing HBOC-201 was supplemented w
ith various therapeutic drugs and assayed for these agents. The result
s of these studies demonstrate that the presence of HBOC-201 in blood
components does not result in significant analytical interference that
would be of concern with many clinical assays at HBOC-201 concentrati
ons encountered during routine clinical use of this RBC replacement so
lution in patients.